Study objective: To evaluate the extent to which high-resolution CT (HRCT) can predict the clinical outcome of bronchoscopic treatment with curative intent in patients with intraluminal typical bronchial carcinoid tumors. Design: An observational study. Setting: Bronchoscopy unit and radiology department of a university hospital. Patients and interventions: Eighteen patients with intraluminal typical bronchial carcinoid tumors in the absence of nodal and distant disease were treated with bronchoscopic electrocautery or Nd-YAG laser as an alternative to surgical resection. Prior to treatment, HRCT was performed. Results: In 10 patients, HRCT showed no peribronchial tumor extension, and 9 of these patients were found to be tumor free after bronchoscopic treatment. So far during follow-up, none of these patients has had a recurrence of the tumor. The median duration of follow-up was 33 months (range, 13 to 68 months). In five patients, HRCT showed signs of peribronchial tumor extension. In three of these patients, specimens taken from biopsies performed after bronchoscopic treatment showed residual tumors, and salvage surgery was carried out. In three patients, HRCT was unable to assess peribronchial tumor extension: in two because of insufficient connective tissue contrast between the hilar structures and in one patient because of suboptimal scan technique. 
B
ronchoscopic treatment has a curative potential in patients with centrally located, intraluminal, early-stage lung cancer. [1] [2] [3] [4] [5] The absence of extraluminal tumor, lymph node metastasis, and distant metastasis is crucial to achieving complete tumor eradication. 6 -8 The success of bronchoscopic treatment also is strongly related to tumor size and location. The accurate assessment of tumor extension prior to bronchoscopic treatment is essential to properly select candidates for this alternative to surgery and to provide an accurate prediction of treatment efficacy. Conventional radiologic examinations and standard CT have been reported to be relatively inaccurate in assessing tumor extension. 9 -11 High-resolution CT (HRCT) provided more accurate information in patients with earlystage squamous cell lung cancer who were referred for bronchoscopic treatment. 12 The same may apply for a subgroup of patients with intraluminal typical bronchial carcinoid (ITBC) tumors. We have reported previously 13 that in patients with ITBC tumors, bronchoscopic treatment resulted in the histologically confirmed disappearance of tumors in patients who underwent surgery after bronchoscopic treatment. Recently, we have confirmed the curative potential of bronchoscopic treatment for ITBC tu-mors as an alternative to surgical resection in a pilot study. 14 In the present study, the predictive value of HRCT for the clinical outcome of bronchoscopic treatment in patients with ITBC tumors was examined.
Materials and Methods
Eighteen patients, 11 men and 7 women, with a median age of 44 years (range, 20 to 74 years) with ITBC tumors were treated bronchoscopically with curative intent. Patients were referred from other hospitals in the Netherlands to our department for bronchoscopic treatment. Tumors were accessible for the fiberoptic bronchoscope, and conventional CT showed no signs of extraluminal tumor extension or nodal enlargement (Ͼ 1 cm). 14 Patients underwent additional HRCT scanning (Somaton Plus(R); Siemens; Erlangen, Germany). Data acquisition was obtained with the spiral technique using the following factors: mA, 145; kilovolt, 137; table feed, 2 mm; and slice thickness and reconstruction, 2 mm (pitch, 1 mm). Further details about the scan technique have been described elsewhere. 12 Images were reevaluated by an experienced radiologist without knowledge of the bronchoscopic treatment outcome. The radiologist described tumors as being invisible, strictly intraluminal, or partly extraluminal. An extraluminal tumor was thought to be present in the case of bronchial wall irregularities or with the presence of extraluminal tissue with the same density and contrast enhancement as the intraluminal tissue. Extraluminal tissue that showed the same degree of enhancement as intraluminal tumor was considered to have an identical vascular pattern with regard to contrast access to both the capillary network and the extracapillary interstitial space. Nodal enlargement was described when present. Bronchoscopy was performed prior to treatment, and tumors were assessed in terms of location and size.
Bronchoscopic treatment was carried out using Nd-YAG laser, electrocautery, or both. No more than two bronchoscopic treatment sessions were carried out within a maximum period of 2 months. Surgical resection was performed without delay in cases in which the tumor persisted after two bronchoscopic treatment sessions or after 2 months.
A complete response was defined when bronchoscopy, histology specimen, and radiologic examinations showed no signs of tumor persistence or recurrence during follow-up. Postbronchoscopic treatment evaluations consisted of bronchoscopy, chest radiograph, and CT. Follow-up bronchoscopies were carried out once at 3 to 4 weeks after bronchoscopic treatment, at 3-month intervals during the first year after bronchoscopic treatment, and every 6 months thereafter. HRCT findings prior to treatment with and after the outcome of bronchoscopic treatment, with a minimum follow-up of 12 months, were compared.
Results
Locations of tumors are shown in Table 1 . Mean tumor size was 1.4 cm (range, 0.4 to 2.0 cm). The results of HRCT and bronchoscopic treatment are shown in Table 1 . Overall, the success rate for bronchoscopic treatment was 72% (95% confidence interval, 47 to 90%). None of the HRCT scans showed lymph nodes that were Ͼ 1 cm in diameter. In 10 patients, HRCT showed no signs of peribronchial tumor extension, and in this subgroup the success rate of bronchoscopic treatment was 90% (95% confidence interval, 56 to 100%). Median follow-up after bronchoscopic treatment has been 33 months (range, 13 to 68 months). The tumor was invisible on HRCT scan in four of these patients. In only one patient with no signs of extraluminal tumor did bronchoscopic treatment fail to achieve a complete response. In that case, the tumor was located in a segmental bronchus, and the distal tumor margin was difficult to assess bronchoscopically. In five patients, HRCT showed signs of extraluminal tumor extension. Bronchoscopic treatment could not achieve a complete response in three of these patients, and salvage surgery was necessary. The sign of extraluminal tumor extension in these three patients was extraluminal tissue with the same density and contrast enhancement as the intraluminal tumor. In one of the three patients, the definite diagnosis after surgery proved to be atypical carcinoid tumor, which contrasted with the diagnosis prior to resection. In three patients, HRCT was not able to assess peribronchial tumor extension: in two patients because of insufficient connective tissue contrast between the hilar structures, and in the other patient because of suboptimal scan technique. Tumor location and tumor size were also predictors of successful bronchoscopic treatment. In all five patients in whom bronchoscopic treatment failed, the tumor was located in a segmental bronchus, and the distal tumor margin was difficult to assess. Of eight patients who had tumors that were Յ 1 cm in diameter, bronchoscopic treatment failed to achieve complete response in only one patient. Of 10 patients who had tumors that were Ͼ 1 cm in diameter, bronchoscopic treatment failed to achieve complete response in 4 patients.
Discussion
This study confirms the assumption that HRCT findings predict clinical outcome of bronchoscopic treatment in patients with ITBC tumors. When HRCT showed a strictly intraluminal tumor, bronchoscopic treatment could achieve clinical complete response in all cases except one. In this subject, the tumor was located in a segmental bronchus and the distal tumor margin was difficult to assess. However, HRCT was not conclusive when signs of extraluminal tumor were found. In two patients, bronchoscopic treatment achieved complete response despite signs of extraluminal tumor on HRCT. CT with the highresolution technique provided additional information regarding tumor extension. In five patients in whom conventional CT showed no extraluminal tumor, HRCT showed signs of extraluminal tumor. However, in all these cases, the radiologist had difficulty in distinguishing the tumor from atelectasis. This is understandable since both atelectasis and tumor can be indistinguishable even on HRCT. Complete response could only be achieved in two of the five patients with signs of extraluminal tumor on HRCT.
Accurate assessment of tumor extension is crucial in selecting patients with ITBC tumors who would be suitable for bronchoscopic treatment and in properly determining its effectiveness compared to standard treatment. HRCT provides a better spatial resolution in part by using a different reconstruction algorithm. The optimal judgment of extraluminal tumor growth requires an experienced radiologist with knowledge of the technique and this specific indication. The indications for and limitations of bronchoscopic treatment with curative intent have been addressed before. 15 The success rate of bronchoscopic treatment depends not only on the peribronchial extension of the tumor, but also on its malignant behavior, location, and size. Early-stage squamous cell lung cancer tumors that are Յ 3 mm thick and have a longitudinal axis Յ 20 mm have been shown not to have lymph node metastasis. 6 -8 Therefore, bronchoscopic treatment has been proposed as a "tissue-sparing" treatment alternative to surgical resection in this category of patients. Regardless of the technique of choice, eg, photodynamic therapy, brachytherapy, Nd-YAG laser, or electrocautery, complete tumor eradication is the ultimate goal. 15 This goal also may apply to a subgroup of patients with ITBC tumors in whom the tumor is strictly intraluminal, mural, pedunculated, or sessile and is easily accessible for the bronchoscope, as has been reported recently. 14 In our present series, the inclusion criteria for bronchoscopic treatment were similar to those used in early-stage squamous cell lung cancer; ie, tumors were intraluminal without signs of peribronchial tumor on conventional CT and never exceeded 2 cm in diameter.
In-depth necrosis of several millimeters can be obtained by endoscopic techniques such as Nd-YAG laser or bronchoscopic electrocautery. These techniques have been proven to be potentially curative in patients with early-stage squamous cell lung cancer and ITBC tumors. 14, 16 Longer follow-up is necessary to determine whether this technique is as effective as surgical resection in a subgroup of patients with ITBC tumors, as the typical carcinoid tumor is very slow growing. Nevertheless, the time of survival after bronchoplastic surgery, together with the low rate of lymph node invasion and metastasis of the typical carcinoid tumor, the central localization, and the tendency for endobronchial polypoid growth within the large airways justify consideration of bronchoscopic treatment as a potentially tissue-sparing alternative for surgery. [17] [18] [19] In our opinion HRCT should be performed in patients with ITBC tumors to assess the tumor more accurately and to estimate the likelihood of achieving complete tumor eradication with bronchoscopic treatment. Slight signs of peribronchial tumor should not automatically exclude a patient from bronchoscopic treatment with curative intent, especially when bronchoscopic accessibility is excellent and tumor debulking is initially acceptable before the final decision to proceed to surgical resection.
